Cytek Biosciences Q2 Revenue Up 6%, Raises Full-Year Guidance Midpoint by $1M
CTKB sits 28% above its 52-week low of $3.28.
Summary
Cytek Biosciences reported Q2 2026 revenue of $48.1 million (+6% YoY), improved gross margins, but a wider net loss of $12.2 million. Full-year revenue guidance was raised slightly to $207–$212 million.
Key Events · Earnings and Guidance · CTKB
-
Q2 Revenue +6% to $48.1M
Revenue rose 6% year-over-year to $48.1 million, driven by instrument growth in the U.S. and China and continued service expansion.
-
Gross Margin Improves, Loss Widens
GAAP gross margin improved to 59% from 52%, but net loss widened to $12.2 million from $5.6 million due to a 15% increase in operating expenses, including litigation and severance costs.
-
Full-Year Guidance Raised Modestly
Cytek raised its 2026 revenue guidance to $207–$212 million, a $1 million increase at the midpoint, reflecting confidence in new product launches.
-
Strong Cash Position
Cash, equivalents, and marketable securities totaled $262.0 million as of June 30, 2026, providing ample runway despite widening losses.
Analysis · CTKB · Industrial Applications And Services
Cytek Biosciences delivered a mixed quarter: revenue grew 6% to $48.1 million, driven by instrument strength in the U.S. and China, and recurring revenue reached 35% of trailing-12-month sales. Gross margins improved sharply — GAAP 59% vs 52% a year ago — but operating expenses jumped 15%, pushing the net loss to $12.2 million from $5.6 million. The company raised its full-year revenue outlook to $207–$212 million, a modest $1 million midpoint increase, signaling confidence in new product launches like the Cytek Borealis. With $262 million in cash, the balance sheet remains solid, but widening losses and a recent senior sales executive departure add caution.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTKB was trading at $4.20 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $539.8M. The 52-week trading range was $3.28 to $6.18. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.